Lineage Cell Therapeutics Inc.
LCTX | AMEX
$1.01
-$0.02 (-1.94%)
At close: Sep 21, 2026, 4:00 PM ET
$1.04
+$0.03 (+2.97%)
Pre-market:
Sep 22, 2026, 5:19 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 14.56M | 9.5M | 8.95M | 14.7M | 3.9M | 773K |
Cost of Revenue | 845K | 334K | 671K | 728K | 1.43M | 385K |
Gross Profit | 13.71M | 9.17M | 8.27M | 13.98M | 2.47M | 388K |
Operating Income | -21.78M | -21.48M | -24.73M | -22.52M | -49.21M | -26.45M |
Interest Income | 1.69M | 1.72M | 1.63M | 829K | 2K | 1.04M |
Pretax Income | -68.65M | -18.58M | -23.28M | -25.81M | -43.27M | -21.92M |
Net Income | -63.53M | -18.61M | -21.49M | -26.27M | -43.02M | -20.65M |
Selling & General & Admin | 18.46M | 18.17M | 17.3M | 22.51M | 18.21M | 15.57M |
Research & Development | 17.73M | 12.47M | 15.71M | 13.99M | 33.91M | 12.32M |
Other Expenses | -699K | n/a | n/a | n/a | -445K | -1.05M |
Operating Expenses | 35.49M | 30.64M | 33.01M | 36.5M | 51.68M | 26.84M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 36.34M | 30.98M | 33.68M | 37.22M | 53.11M | 27.22M |
Income Tax Expense | -5.11M | n/a | -1.8M | 541K | n/a | -1.24M |
Shares Outstanding (Basic) | 230.12M | 200.19M | 172.66M | 169.79M | 164.5M | 150.04M |
Shares Outstanding (Diluted) | 230.12M | 200.19M | 172.66M | 169.79M | 164.5M | 150.04M |
EPS (Basic) | -0.28 | -0.09 | -0.12 | -0.15 | -0.26 | -0.14 |
EPS (Diluted) | -0.28 | -0.09 | -0.12 | -0.15 | -0.26 | -0.14 |
EBITDA | -67.95M | -17.97M | -22.59M | -25.09M | -42.4M | -24.41M |
EBIT | -68.65M | -18.58M | -23.28M | -25.81M | -43.27M | -26.45M |
Depreciation & Amortization | 699K | 609K | 692K | 727K | 873K | 2.04M |
Add to Watchlist
Select watchlists to add or remove LCTX